Luoxin Pharmaceuticals Group Stock Past Earnings Performance
Past criteria checks 0/6
Luoxin Pharmaceuticals Group Stock's earnings have been declining at an average annual rate of -61.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 26.3% per year.
Key information
-61.3%
Earnings growth rate
-64.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -26.3% |
| Return on equity | -37.1% |
| Net Margin | -28.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Luoxin Pharmaceuticals Group Stock makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,418 | -697 | 1,420 | 70 |
| 30 Jun 24 | 2,368 | -623 | 1,305 | 80 |
| 31 Mar 24 | 2,390 | -608 | 1,328 | 89 |
| 31 Dec 23 | 2,364 | -661 | 1,393 | 112 |
| 30 Sep 23 | 1,644 | -957 | 1,316 | 124 |
| 30 Jun 23 | 1,700 | -1,234 | 1,317 | 143 |
| 31 Mar 23 | 2,073 | -1,397 | 1,481 | 187 |
| 01 Jan 23 | 3,588 | -1,225 | 2,249 | 205 |
| 30 Sep 22 | 5,155 | -528 | 2,391 | 267 |
| 30 Jun 22 | 6,177 | -9 | 2,587 | 299 |
| 31 Mar 22 | 6,912 | 330 | 2,698 | 313 |
| 01 Jan 22 | 6,478 | 406 | 2,331 | 321 |
| 30 Sep 21 | 6,830 | 414 | 2,590 | 324 |
| 30 Jun 21 | 6,860 | 403 | 2,746 | 326 |
| 31 Mar 21 | 6,564 | 366 | 2,693 | 329 |
| 31 Dec 20 | 6,096 | 321 | 2,403 | 361 |
| 30 Sep 20 | 6,320 | 577 | 2,525 | 360 |
| 30 Jun 20 | 6,338 | 555 | 2,624 | 382 |
| 31 Mar 20 | 7,062 | 620 | 3,218 | 405 |
| 31 Dec 19 | 7,589 | 634 | 3,611 | 420 |
| 30 Sep 19 | 8,502 | 629 | 4,349 | 524 |
| 30 Jun 19 | 9,680 | 752 | 5,221 | 621 |
| 31 Mar 19 | 7,782 | 611 | 4,111 | 522 |
| 31 Dec 18 | 6,211 | 512 | 3,297 | 420 |
| 31 Mar 17 | 4,387 | 345 | 3,015 | 0 |
| 31 Dec 16 | 4,118 | 379 | 2,774 | 0 |
| 30 Sep 16 | 3,888 | 416 | 2,461 | 0 |
| 30 Jun 16 | 3,787 | 468 | 2,260 | 0 |
| 31 Mar 16 | 3,767 | 502 | 2,095 | 0 |
| 31 Dec 15 | 3,611 | 493 | 2,013 | 0 |
| 30 Sep 15 | 3,356 | 474 | 1,797 | 0 |
| 30 Jun 15 | 3,057 | 446 | 1,663 | 0 |
| 31 Mar 15 | 2,900 | 430 | 1,630 | 0 |
| 31 Dec 14 | 2,767 | 444 | 1,470 | 0 |
| 30 Sep 14 | 2,757 | 402 | 1,442 | 0 |
| 30 Jun 14 | 2,724 | 411 | 1,329 | 0 |
| 31 Mar 14 | 2,554 | 420 | 1,204 | 0 |
| 31 Dec 13 | 2,529 | 429 | 1,203 | 0 |
Quality Earnings: 002793 is currently unprofitable.
Growing Profit Margin: 002793 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002793 is unprofitable, and losses have increased over the past 5 years at a rate of 61.3% per year.
Accelerating Growth: Unable to compare 002793's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002793 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 002793 has a negative Return on Equity (-37.14%), as it is currently unprofitable.